Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (Master Protocol Revised version 05 dated 16-Feb-2017 + Sub-protocol Revised version 03 dated 16-Feb-2017 + Sub-protocol B Initial version dated 31-May-2017)

Next Previous
X
Search
Trial Profile

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (Master Protocol Revised version 05 dated 16-Feb-2017 + Sub-protocol Revised version 03 dated 16-Feb-2017 + Sub-protocol B Initial version dated 31-May-2017)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Dasatinib; Ipilimumab; Linrodostat; Relatlimab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms FRACTION-Lung
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 23 Feb 2021 Status changed from active, no longer recruiting to discontinued.
    • 20 Dec 2019 This trial is completed in Spain, according to European Clinical Trials Database record.
    • 13 Nov 2019 This trial has been completed in Austria, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top